Fate Therapeutics, Inc.
FATEHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Fate Therapeutics, Inc. focuses on Biotechnology services and products. Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. Valued at $252.8M, FATE is a micro-cap name in its sector. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Market Cap
$252.8M
Beta
2.53
P/E (TTM)
—
P/E (Fwd)
-2.18
EPS (TTM)
$-1.05
EPS (Fwd)
$-0.97
ROE
-60.8%
ROA
-26.2%
Cash
$153.8M
Total Debt
$75.7M
Free CF
-$48.7M
52W Change
27.9%
Annual Financials
Cash vs Debt
Where FATE stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FATE finished 13.08% below its 150-day moving average ($2.14) and 2.62% below its 200-day moving average ($1.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FATE overbought or oversold?
At the October 20, 2026 close, FATE's RSI(14) was 24.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Fate Therapeutics, Inc. holds $153.8M in cash against $75.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$48.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -60.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $96.3M (2022) to $6.6M (2025), a 93% decline worth watching.
Fate Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, FATE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FATE.